Trial Profile

A Phase I/II Study of Pembrolizumab (MK-3475) in Japanese Pediatric Participants With Specific Solid Tumors or Lymphomas, or in Japanese Adult Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-G21)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 18 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications B-cell lymphoma; Hodgkin's disease; Lymphoma; Malignant melanoma; Merkel cell carcinoma; Skin cancer; Solid tumours
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Acronyms KEYNOTE-G21
Sponsors Merck Sharp & Dohme

03 Mar 2026 Planned initiation date changed from 26 Feb 2026 to 31 Mar 2026.
19 Feb 2026 Planned initiation date changed from 20 Feb 2026 to 26 Feb 2026.
19 Feb 2026 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com